{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:42:54Z","timestamp":1791934974312,"version":"4.3.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:p>\n            Hypertension and atrial fibrillation predict major adverse events independently. Visit-to-visit variability (VVV) in systolic blood pressure (SBP) predicts outcomes beyond SBP itself, but risk associated with SBP-VVV in atrial fibrillation remains uncertain. We evaluated relationships between SBP-VVV, quality of oral anticoagulation control, and outcomes in patients with atrial fibrillation. Data from the AFFIRM trial (atrial fibrillation follow-up investigation of rhythm management) were analyzed. SBP-VVV was defined according to SD of SBP (SBP-SD) during follow-up. SBP-VVV was categorized by quartiles (1st, &lt;10.09; 2nd, 10.09\u201313.85; 3rd, 13.86\u201317.33; and 4th, \u226517.34 mm Hg) and as a continuous variable. Among the original cohort, 3843 (94.7%) patients were eligible. Time in therapeutic range and percentage of international normalized ratio in range were progressively lower by quartiles (both\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). An inverse linear association existed between SBP-SD and time in therapeutic range\/percentage of international normalized ratio in range (\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). After a median (interquartile range) follow-up of 3.6 (2.7\u20134.6) years, stroke and major bleeding rates progressively increased by SBP-VVV quartile (both\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). Patients in the 4th quartile had the highest rate of cardiovascular and all-cause death (\n            <jats:italic>P<\/jats:italic>\n            =0.005 and\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). A Cox multivariate analysis confirmed that 3rd and 4th quartiles were associated independently with a higher risk for stroke (\n            <jats:italic>P<\/jats:italic>\n            =0.042 and\n            <jats:italic>P<\/jats:italic>\n            =0.004) and major bleeding (\n            <jats:italic>P<\/jats:italic>\n            =0.009 and\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). Patients in 4th quartile had also a higher risk for all-cause death (\n            <jats:italic>P<\/jats:italic>\n            =0.048). SBP-SD as a continuous variable was associated with increased risk for all outcomes. In conclusion, SBP-VVV is inversely associated with quality of anticoagulation control and independently predicts major adverse outcomes. Management of blood pressure variability may improve outcomes in atrial fibrillation.\n          <\/jats:p>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT00000556.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/hypertensionaha.117.10106","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T01:11:48Z","timestamp":1507079508000},"page":"949-958","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation"],"prefix":"10.1161","volume":"70","author":[{"given":"Marco","family":"Proietti","sequence":"first","affiliation":[{"name":"From the Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (M.P., G.F.R., G.Y.H.L.); Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City (B.O.); and Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Denmark (G.Y.H.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Francesco","family":"Romiti","sequence":"additional","affiliation":[{"name":"From the Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (M.P., G.F.R., G.Y.H.L.); Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City (B.O.); and Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Denmark (G.Y.H.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Olshansky","sequence":"additional","affiliation":[{"name":"From the Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (M.P., G.F.R., G.Y.H.L.); Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City (B.O.); and Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Denmark (G.Y.H.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[{"name":"From the Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (M.P., G.F.R., G.Y.H.L.); Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City (B.O.); and Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Denmark (G.Y.H.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpx013"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl504"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002015"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.07.032"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004075"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.054"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001159"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.796185"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164076"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.10.029"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00082-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.044"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651587"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.04.013"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.04.013"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.013173"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.115.06960"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.03.038"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074037"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.124750"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2011.03.001"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.10.033"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpt040"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2011.135"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.26.991"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1421"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30754-7"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.117.10106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:29:12Z","timestamp":1715592552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.117.10106"}},"subtitle":["The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management)"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.117.10106"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.117.10106","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}